| scholarly article | Q13442814 |
| P50 | author | Sherene Loi | Q42315566 |
| Phillip K. Darcy | Q42683557 | ||
| Henry Leonidas Gómez | Q43270076 | ||
| Mónica Valeria Estrada | Q56851379 | ||
| Roberto C Salgado-Delgado | Q87734996 | ||
| Justin M. Balko | Q90244216 | ||
| Paul A Beavis | Q90856136 | ||
| Simon A. Mallal | Q91272953 | ||
| Sathana Dushyanthen | Q96251208 | ||
| P2093 | author name string | Kai Wang | |
| Carsten Denkert | |||
| David L Rimm | |||
| Vincent A Miller | |||
| Carlos L Arteaga | |||
| Phil J Stephens | |||
| Sergey V Ryzhov | |||
| Melinda E Sanders | |||
| Peter Savas | |||
| Rebecca S Cook | |||
| Violeta Sánchez | |||
| Susan Combs | |||
| Roman Yelensky | |||
| Jennifer M Giltnane | |||
| Franco D Doimi | |||
| Mark A Pilkinton | |||
| P2860 | cites work | Comprehensive molecular portraits of human breast tumours | Q24630844 |
| Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer | Q33875120 | ||
| A public genome-scale lentiviral expression library of human ORFs | Q33943308 | ||
| Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. | Q34172008 | ||
| Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer | Q34270064 | ||
| PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer | Q34454922 | ||
| Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer | Q34616067 | ||
| The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. | Q35052176 | ||
| PD-L1 expression is increased in a subset of basal type breast cancer cells | Q35097436 | ||
| Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors | Q35906418 | ||
| Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma | Q36612452 | ||
| Mutant MHC class II epitopes drive therapeutic immune responses to cancer | Q36817092 | ||
| Molecular and genetic properties of tumors associated with local immune cytolytic activity | Q36869059 | ||
| Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance | Q36957198 | ||
| CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer | Q36991010 | ||
| (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway | Q37112466 | ||
| The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. | Q37451618 | ||
| Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study | Q37600494 | ||
| Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets | Q37624234 | ||
| PD-L1 expression in triple-negative breast cancer | Q37724790 | ||
| The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. | Q39130461 | ||
| MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC. | Q39869672 | ||
| Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy | Q42182888 | ||
| Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors | Q43546471 | ||
| Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial | Q43951696 | ||
| Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98 | Q46389190 | ||
| Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer | Q46771645 | ||
| PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. | Q47573421 | ||
| Automated subcellular localization and quantification of protein expression in tissue microarrays | Q52030096 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cooperation | Q380962 |
| triple-negative breast cancer | Q7843332 | ||
| P304 | page(s) | 1499-1509 | |
| P577 | publication date | 2015-10-29 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors | |
| P478 | volume | 22 |
| Q41918758 | A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer |
| Q46894943 | A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease. |
| Q49721138 | Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers |
| Q41701208 | Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer |
| Q90023691 | Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial |
| Q57109579 | Autoantibodies as Potential Biomarkers in Breast Cancer |
| Q52679779 | BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment. |
| Q92578246 | BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts |
| Q93335001 | Biological Consequences of MHC-II Expression by Tumor Cells in Cancer |
| Q38628198 | Breast Cancer Immunotherapy: Facts and Hopes |
| Q26745442 | Checkpoint Inhibitors and Their Application in Breast Cancer |
| Q38639746 | Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions |
| Q28072263 | Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer |
| Q38669465 | Clinical relevance of host immunity in breast cancer: from TILs to the clinic |
| Q60919807 | Clinical verification of the relationship between smoking and the immune microenvironment of breast cancer |
| Q38634557 | Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond |
| Q89457550 | Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer |
| Q47217165 | Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer |
| Q48231859 | DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer |
| Q57071375 | Distribution of CD4 and CD8 exhausted tumor-infiltrating lymphocytes in molecular subtypes of Chinese breast cancer patients |
| Q42243444 | Dramatic response of metaplastic breast cancer to chemo-immunotherapy |
| Q65000057 | ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer. |
| Q55238772 | Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer. |
| Q54978022 | Effect of aromatase inhibitor letrozole on the proliferation of spermatogonia by regulating the MAPK pathway. |
| Q41291930 | Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. |
| Q50058145 | Emerging biomarkers for cancer immunotherapy in melanoma. |
| Q49710595 | Expression of MAGE-A and NY-ESO-1 cancer-testis antigens is enriched in triple-negative invasive breast cancers |
| Q55383509 | Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer. |
| Q60044568 | Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy |
| Q88684372 | Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations |
| Q59800659 | Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine |
| Q54965602 | How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. |
| Q54947687 | Immune cell profiling in cancer: molecular approaches to cell-specific identification. |
| Q99408679 | Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers |
| Q53111596 | Immunotherapy for Colorectal Cancer |
| Q92503954 | Immunotherapy in breast cancer |
| Q99551766 | Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and genetic characterization |
| Q90468395 | Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma |
| Q64103583 | Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer |
| Q92857735 | Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer? |
| Q48269487 | Is there a role for single-agent MEK inhibition in melanoma? |
| Q26751520 | KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment |
| Q50513362 | Learning from PD-1 Resistance: New Combination Strategies. |
| Q56889985 | MEK inhibitors for the treatment of NRAS mutant melanoma |
| Q37712385 | Mechanism of immune evasion in breast cancer |
| Q98771234 | Mechanisms of Cancer Resistance to Immunotherapy |
| Q52707883 | Mechanisms of Resistance to PD-1 and PD-L1 Blockade. |
| Q55347716 | Mechanisms of immune evasion in breast cancer. |
| Q92875307 | Mechanisms of immunogenicity in colorectal cancer |
| Q42513445 | Metalloprotease-dependent activation of EGFR modulates CD44+/CD24- populations in triple negative breast cancer cells through the MEK/ERK pathway. |
| Q37691434 | MicroRNA-29c-5p suppresses gallbladder carcinoma progression by directly targeting CPEB4 and inhibiting the MAPK pathway |
| Q57815585 | Molecular determinants of post-mastectomy breast cancer recurrence |
| Q41660755 | Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study. |
| Q58613793 | Mutational activation of the EGFR down-regulates MHC class I expression via the ERK in non-small cell lung cancer |
| Q34549227 | New Immunotherapy Strategies in Breast Cancer |
| Q33869781 | New insights into the role of EMT in tumor immune escape. |
| Q88952320 | OncoKB: A Precision Oncology Knowledge Base |
| Q39438805 | Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer |
| Q90722217 | Oxidation Stress-Mediated MAPK Signaling Pathway Activation Induces Neuronal Loss in the CA1 and CA3 Regions of the Hippocampus of Mice Following Chronic Cold Exposure |
| Q64120108 | PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications |
| Q91713968 | PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours |
| Q38818203 | Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development |
| Q47701712 | Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer |
| Q57105411 | Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer |
| Q41545839 | Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy |
| Q47101836 | Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM). |
| Q92425490 | Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers |
| Q55238969 | Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy. |
| Q94483697 | Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy |
| Q90321516 | Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma |
| Q90720634 | Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer |
| Q93147363 | Recent Findings in the Regulation of Programmed Death Ligand 1 Expression |
| Q64059605 | Recent advances in triple negative breast cancer: the immunotherapy era |
| Q49887919 | Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors |
| Q52725238 | Regulation and Function of the PD-L1 Checkpoint. |
| Q92316377 | Regulation of Immunity in Breast Cancer |
| Q64887142 | Relationship between Tumor Infiltrating Lymphocytes and Progression in Breast Cancer. |
| Q98466646 | Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors |
| Q45974765 | Rho GTPase effectors and NAD metabolism in cancer immune suppression. |
| Q37675926 | Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. |
| Q92404971 | TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2 |
| Q39125149 | Targeting A2 adenosine receptors in cancer |
| Q54977309 | Targeting Forkhead Box M1 Transcription Factor in Breast Cancer. |
| Q92349505 | Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy |
| Q90677046 | The Immune Landscape in Women Cancers |
| Q90133583 | The Immune Microenvironment of Breast Cancer Progression |
| Q38621231 | The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment |
| Q101574526 | The cutting-edge progress of immune-checkpoint blockade in lung cancer |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
| Q59807467 | The role of autophagy in the treatment of BRAF mutant colorectal carcinomas differs based on microsatellite instability status |
| Q57060145 | Therapeutic strategies to target RAS-mutant cancers |
| Q54979386 | Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion. |
| Q56594845 | Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics |
| Q33769821 | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease |
| Q28554412 | Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes |
| Q92266207 | Tumor intrinsic immunity related proteins may be novel tumor suppressors in some types of cancer |
| Q94475710 | Tumor mutational burden and immune signatures interplay in renal cell carcinoma |
| Q38734804 | Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. |
| Q61456224 | Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement |
| Q90644277 | Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer |
| Q90108782 | USP11 promotes growth and metastasis of colorectal cancer via PPP1CA-mediated activation of ERK/MAPK signaling pathway |
| Q50186375 | Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells. |
| Q47566725 | Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition |
| Q89367022 | miR-135 promotes proliferation and stemness of oesophageal squamous cell carcinoma by targeting RERG |
Search more.